Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24916039 | 0.82 | NOS3 (0.36) | LOXL2LOXNOS3NOS1NOS2 | |
| SCHEMBL24915961 | 0.82 | SLC6A4 (0.40) | — | |
| SCHEMBL24915646 | 0.74 | P2RX3 (0.37) | KDM4EMEN1KMT2A | |
| SCHEMBL24915937 | 0.73 | PTGDR2 (0.34) | CCR1CCR5CCR8 | |
| SCHEMBL24916221 | 0.72 | ACE2 (0.42) | KDM4EMEN1KMT2A | |
| SCHEMBL28221332 | 0.68 | PSMD14 (0.57) | CCR1CCR5CCR8KDM4EMEN1 | |
| SCHEMBL24482795 | 0.68 | PDE2A (0.35) | LOXL2CCR1CCR5CCR8KDM4E | |
| SCHEMBL24916430 | 0.68 | NSD2 (0.39) | CCR1CCR5CCR8KDM4E | |
| SCHEMBL3849204 | 0.68 | SLC6A2 (0.50) | LOXL2KDM4E | |
| SCHEMBL19447850 | 0.67 | ADRA1A (0.51) | CCR1CCR5CCR8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | LOXL2 2808/4885LOX 3381/4885CCR1 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.